We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Seegene Launches New COVID-19 PCR Test with Reduced Turnaround Time Optimized for Mass Testing

By LabMedica International staff writers
Posted on 20 Jan 2022
Print article
Image: Allplex SARS-CoV-2 Fast PCR Assay (Photo courtesy of Seegene, Inc.)
Image: Allplex SARS-CoV-2 Fast PCR Assay (Photo courtesy of Seegene, Inc.)

Seegene, Inc. (Seoul, Korea) has launched the new Allplex SARS-CoV-2 Fast PCR Assay that can deliver PCR results in just 60 minutes.

The assay is expected to reduce the total turnaround time to a third and expand testing capacity up to three times for hospitals and laboratories without additional instruments or compromise on accuracy, according to the company. The Allplex SARS-CoV-2 Fast PCR Assay targets three COVID-19 genes - E, RdRP, and N - to reliably detect COVID-19 regardless of the variants.

Reduction of the turnaround time can be attributed to the application of a novel enzyme developed by Seegene, which reduces PCR process time to half, as well as the company’s innovative extraction-free method that makes the Allplex SARS-CoV-2 Fast PCR Assay be available without the extraction of the sample preparation in PCR-based tests. This drastically reduces the total turnaround time for each result. As such, the new assay lessens the amount of hands-on processing time required, allowing facilities to triple their testing capacity in the same hour.

"This assay will be the optimized choice for laboratories and hospitals where they conduct large-scale testing as it helps them immediately expand the testing capacity with lessening the burden of healthcare workers," said Ho Yi, Chief Sales and Marketing Officer of Seegene. "For the time being, we plan to target large-scale testing markets in more than 60 countries all across the globe. The next step in our journey is to develop a new gold-standard molecular diagnostic assay that fully matches the speed of antigen tests with the same degree of accuracy as PCR test."

Related Links:
Seegene, Inc. 

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
SARS-CoV-2 RT-PCR Assay
Reliance SARS-CoV-2 RT-PCR Assay Kit

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: The utilization of liquid biopsies in cancer research is a rapidly developing field (Photo courtesy of Lightspring/Shutterstock)

Blood Samples Enhance B-Cell Lymphoma Diagnostics and Prognosis

B-cell lymphoma is the predominant form of cancer affecting the lymphatic system, with about 30% of patients with aggressive forms of this disease experiencing relapse. Currently, the disease’s risk assessment... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Pathology

view channel
Image: The Sampler device could revolutionize sample collection for diagnostic tests (Photo courtesy of ReadyGo Diagnostics)

First of Its Kind Universal Tool to Revolutionize Sample Collection for Diagnostic Tests

The COVID pandemic has dramatically reshaped the perception of diagnostics. Post the pandemic, a groundbreaking device that combines sample collection and processing into a single, easy-to-use disposable... Read more